MCID: LVR013
MIFTS: 68

Liver Disease

Categories: Blood diseases, Bone diseases, Gastrointestinal diseases, Genetic diseases, Liver diseases, Metabolic diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Liver Disease

MalaCards integrated aliases for Liver Disease:

Name: Liver Disease 12 15 37 17
Liver Diseases 54 42 43 71
Abnormality of the Liver 29 6
Liver Dysfunction 54 71
Liver Failure 54 71
Disorder of Liver 12
Hepatic Disorder 12
Hepatic Failure 29
Hepatic Disease 15

Classifications:



External Ids:

Disease Ontology 12 DOID:409
ICD9CM 34 573.9
MeSH 43 D008107
NCIt 49 C3196
SNOMED-CT 67 235856003
UMLS 71 C0023895 C0085605 C0086565

Summaries for Liver Disease

MedlinePlus : 42 Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. There are many kinds of liver diseases: Diseases caused by viruses, such as hepatitis A, hepatitis B, and hepatitis C Diseases caused by drugs, poisons, or too much alcohol. Examples include fatty liver disease and cirrhosis. Liver cancer Inherited diseases, such as hemochromatosis and Wilson disease Symptoms of liver disease can vary, but they often include swelling of the abdomen and legs, bruising easily, changes in the color of your stool and urine, and jaundice, or yellowing of the skin and eyes. Sometimes there are no symptoms. Tests such as imaging tests and liver function tests can check for liver damage and help to diagnose liver diseases.

MalaCards based summary : Liver Disease, also known as liver diseases, is related to fatty liver disease and polycystic liver disease, and has symptoms including nausea and vomiting, abdominal pain and constipation. An important gene associated with Liver Disease is MEG3 (Maternally Expressed 3), and among its related pathways/superpathways are Folate Metabolism and FOXA2 and FOXA3 transcription factor networks. The drugs Prednisolone phosphate and Methylprednisolone have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and kidney, and related phenotypes are cellular and homeostasis/metabolism

Wikipedia : 74 Liver disease (also called hepatic disease) is a type of damage to or disease of the liver. Whenever the... more...

Related Diseases for Liver Disease

Diseases in the Liver Disease family:

Liver Failure, Infantile, Transient Infantile Liver Failure Syndrome 1
Infantile Liver Failure Syndrome 2 Infantile Liver Failure Syndrome 3
Acute Liver Failure

Diseases related to Liver Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1928)
# Related Disease Score Top Affiliating Genes
1 fatty liver disease 35.4 SLC17A5 PNPLA3 INS GPT GGT1 ALB
2 polycystic liver disease 35.3 SERPINA1 SEC63 PRKCSH PKHD1 PKD1 LRP5
3 non-alcoholic fatty liver disease 35.3 PNPLA3 INS GPT GGT1 ALB ADIPOQ
4 polycystic liver disease 1 with or without kidney cysts 35.2 SEC63 PRKCSH PKHD1 PKD1 LRP5
5 fatty liver disease, nonalcoholic 1 35.2 SLC17A5 PNPLA3 INS GPT GGT1 ADIPOQ
6 polycystic kidney disease 4 with or without polycystic liver disease 35.1 SEC63 PRKCSH PKHD1 PKD1 GANAB
7 polycystic kidney disease 2 with or without polycystic liver disease 35.0 SEC63 PRKCSH PKHD1 PKD1
8 polycystic kidney disease 1 with or without polycystic liver disease 35.0 SEC63 PRKCSH PKHD1 PKD1
9 alcoholic hepatitis 34.3 SLC17A5 PNPLA3 GPT GGT1 F2 ALB
10 non-alcoholic steatohepatitis 34.3 PNPLA3 INS GPT GGT1 ALB ADIPOQ
11 primary biliary cirrhosis 33.7 SLC17A5 GPT GGT1 F2 DLAT ALB
12 alpha-1-antitrypsin deficiency 33.7 SERPINA1 GPT F2 ALB
13 hepatic vascular disease 33.6 SERPINA1 PKHD1 GPT GGT1 F2 ALB
14 wilson disease 33.5 PNPLA3 GPT F2 ALB
15 bile acid synthesis defect, congenital, 1 33.5 HSD3B7 GGT1 ALB
16 cholangitis, primary sclerosing 33.4 SERPINA1 GPT GGT1 F2 DLAT ALB
17 alcohol use disorder 33.4 SLC17A5 GPT GGT1 ALB
18 sclerosing cholangitis 33.2 GPT GGT1 F2 ALB ABCB11
19 hepatic encephalopathy 33.2 SLC17A5 GPT F2 ALB
20 acute liver failure 33.2 SLC17A5 GPT F2 ALB
21 hepatorenal syndrome 33.0 GPT F2 ALB
22 congenital hepatic fibrosis 33.0 PKHD1 PKD1
23 autoimmune hepatitis 33.0 SLC17A5 GPT GGT1 F2 DLAT ALB
24 drug-induced hepatitis 32.9 GPT F2 ALB
25 liver cirrhosis 32.9 SLC17A5 SERPINA1 MEG3 GPT GGT1 FAH
26 idiopathic edema 32.7 INS ADIPOQ
27 alcoholic liver cirrhosis 32.6 SLC17A5 PNPLA3 INS GPT F2 ALB
28 viral hepatitis 32.5 SLC17A5 SERPINA1 PNPLA3 INS GPT GGT1
29 portal hypertension 32.5 PNPLA3 PKHD1 INS GPT F2 ALB
30 cholestasis 32.5 SLC17A5 SERPINA1 HSD3B7 GPT GGT1 F2
31 cholangitis 32.4 SLC17A5 GPT GGT1 F2 DLAT ALB
32 hepatic coma 32.3 GPT F2 ALB
33 hepatitis b 32.2 SLC17A5 GPT GGT1 F2 ALB
34 hepatitis a 32.1 INS GPT GGT1 F2 ALB
35 polycystic kidney disease 32.1 PRKCSH PKHD1 PKD1 LRP5 GANAB ALB
36 kidney disease 32.1 PKHD1 PKD1 LRP5 INS GANAB ALB
37 granulomatous hepatitis 32.0 GPT ALB
38 esophageal varix 32.0 SERPINA1 PKHD1 GPT GGT1 F2 ALB
39 biliary atresia 31.9 GPT GGT1 F2 ALB ABCB11
40 autosomal dominant polycystic kidney disease 31.9 PKHD1 PKD1 LRP5 INS GANAB ALB
41 glucose intolerance 31.8 INS GPT ALB ADIPOQ
42 sleep apnea 31.8 INS GPT ALB ADIPOQ
43 body mass index quantitative trait locus 11 31.8 SLC17A5 PNPLA3 INS GPT GGT1 ALB
44 hyperuricemia 31.7 INS GPT GGT1 ALB
45 obstructive jaundice 31.7 SLC17A5 GPT GGT1 F2 ALB
46 hypothyroidism 31.7 INS GPT F2 ALB ADIPOQ
47 bilirubin metabolic disorder 31.7 SLC17A5 GPT GGT1 F2 ALB ABCB11
48 hepatitis e 31.7 GPT GGT1 F2 ALB
49 cholelithiasis 31.7 SERPINA1 INS GPT GGT1 ALB
50 schistosomiasis 31.6 GPT GGT1 F2 ALB

Comorbidity relations with Liver Disease via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Acute Pancreatitis Deficiency Anemia
Familial Atrial Fibrillation Heart Disease
Hepatic Encephalopathy Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Liver Disease:



Diseases related to Liver Disease

Symptoms & Phenotypes for Liver Disease

UMLS symptoms related to Liver Disease:


nausea and vomiting, abdominal pain, constipation, diarrhea, hepatosplenomegaly, icterus, dyspepsia, heartburn, gastrointestinal gas, digestive system symptom, liver tender, abnormal bruising

MGI Mouse Phenotypes related to Liver Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.1 ADIPOQ ALB F2 FAH GGT1 INS
2 homeostasis/metabolism MP:0005376 10.1 ABCB11 ADIPOQ ALB F2 FAH GGT1
3 liver/biliary system MP:0005370 9.93 ABCB11 ADIPOQ ALB FAH HSD3B7 INS
4 mortality/aging MP:0010768 9.86 ABCB11 ADIPOQ ALB DLAT F2 FAH
5 renal/urinary system MP:0005367 9.28 ADIPOQ ALB FAH GGT1 INS PKD1

Drugs & Therapeutics for Liver Disease

Drugs for Liver Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1032)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
2
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
3
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
4
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
5 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
6
Dalteparin Approved Phase 4 9005-49-6
7
Tinzaparin Approved Phase 4 9041-08-1, 9005-49-6 25244225
8
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
9
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
10
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
11
Azithromycin Approved Phase 4 83905-01-5 447043 55185
12
Nitazoxanide Approved, Investigational, Vet_approved Phase 4 55981-09-4 41684
13
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
14
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
15
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
16
Vancomycin Approved Phase 4 1404-90-6 14969 441141
17
Imipenem Approved Phase 4 74431-23-5, 64221-86-9 104838
18
Insulin glulisine Approved Phase 4 207748-29-6
19
Lixisenatide Approved Phase 4 320367-13-3
20
Arsenic trioxide Approved, Investigational Phase 4 1327-53-3 518740
21
Insulin lispro Approved Phase 4 133107-64-9
22
Atenolol Approved Phase 4 29122-68-7 2249
23
Nebivolol Approved, Investigational Phase 4 99200-09-6, 118457-14-0, 152520-56-4 71301
24
Cefotaxime Approved Phase 4 63527-52-6 5742673 456256
25
Cefoxitin Approved Phase 4 35607-66-0 441199
26
Temocillin Approved, Investigational Phase 4 66148-78-5
27
Caspofungin Approved Phase 4 162808-62-0, 179463-17-3 2826718 468682
28
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
29
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
30
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
31
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
32
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
33
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
34
Ethanolamine oleate Approved Phase 4 2272-11-9
35
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
36
Pravastatin Approved Phase 4 81093-37-0 54687
37
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 27284 23925
38
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
39
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
40
Rifampicin Approved Phase 4 13292-46-1 5381226 5458213
41
Baclofen Approved Phase 4 1134-47-0 2284
42
Anidulafungin Approved, Investigational Phase 4 166663-25-8 166548
43
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
44
Liraglutide Approved Phase 4 204656-20-2 44147092
45
Dobutamine Approved Phase 4 34368-04-2 36811
46
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
47
Adefovir dipivoxil Approved, Investigational Phase 4 142340-99-6 60871
48
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
49
Atropine Approved, Vet_approved Phase 4 51-55-8, 5908-99-6 174174
50
Deferiprone Approved Phase 4 30652-11-0 2972

Interventional clinical trials:

(show top 50) (show all 4111)
# Name Status NCT ID Phase Drugs
1 Granulocyte Colony-stimulating Factor(G-CSF) in the Treatment of Hepatic Failure: a Prospective Randomized Controlled Clinical Study Unknown status NCT02331745 Phase 4 Granulocyte colony-stimulating factor;standard treatment
2 THE EFFECT OF DUAL TREATMENT WITH L-CARNITINE AND MAGNESIUM ON Patients With Non Alcoholic Fatty Liver Disease Unknown status NCT01956825 Phase 4
3 Randomised Controlled Study Comparing Use of Popofol Plus Fentanyl Versus Midazolam Plus Fentanyl as Sedation in Diagnostic Endoscopy in Patients With Advanced Liver Disease. Unknown status NCT03063866 Phase 4 Propofol;Midazolam;Fentanyl
4 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
5 Intravenous-Morphine and Glucagon-Usage Enhanced MR Cholangiography Unknown status NCT00155376 Phase 4 morphine and glucagon
6 Evaluation of Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial Unknown status NCT02213224 Phase 4 Perindopril;Telmisartan;Amlodipine
7 Assessment of Coagulation Abnormalities in Acute on Chronic Liver Failure Patients Using Thromboelastography Unknown status NCT02757170 Phase 4
8 Branched-chain Amino Acid (BCAA) on Progression of Advanced Liver Disease (BRAVE): Korean Nation-wide Multicenter Retrospective and Prospective Observational Cohort Study Unknown status NCT02837302 Phase 4 Livact
9 An Randomized Open Label Trial on the Impact of 24 Weeks of Atorvastatin Therapy on Liver Fat Content and Abdominal Fat Content in Patients With Type 2 Diabetes Combined With High LDL-C and Non-alcoholic Fatty Liver Disease Unknown status NCT01720719 Phase 4 atorvastatin;Vitamin E
10 Influence of CYP3A5 Polymorphism on Liver Function Abnormality and the Trough Level Change After Conversion From Tacrolimus (Bid) to Advagraf® (qd) in Stable Liver Transplant Recipients Unknown status NCT02882113 Phase 4 Advagraf
11 A Randomized, Open Label, Phase IV, Multicenter Study for Efficacy and Safety of Lamivudine Versus Entecarvir Therapy in HBV-related Advanced Liver Disease Patients With High Viral Load and Normal or Slightly Elevated Transaminase Unknown status NCT00823550 Phase 4 Entecavir;Lamivudine
12 Effect of Probiotics on Gut-Liver Axis of Alcoholic Hepatitis Unknown status NCT02335632 Phase 4 Probiotics (Lacidofil®);Placebo
13 Entecavir for Patients With Decompensated HBV-Related Cirrhosis:a Prospective Randomized Controlled Trial Unknown status NCT00663182 Phase 4 Entecavir
14 Hepatic Function and Bile Acid in Preterm Infants Receiving Parenteral Lipids Emulsion Unknown status NCT01786759 Phase 4 ClinOleic;Intralipid
15 Development of an Imaging Biomarker for Hepatic Fibrosis Using Gadoxetate Disodium Unknown status NCT01783314 Phase 4
16 Safety of Acamprosate for Alcohol Dependence in the Elderly: An Open-Label Study Unknown status NCT00655967 Phase 4 Acamprosate (Campral);Acamprosate
17 Intravenous Paracetamol Versus Intravenous Dexketoprofen in Patients Presented With Dysmenorrhea in Emergency Department Unknown status NCT02373514 Phase 4 Paracetamol;Dexketoprofen
18 A Randomised Controlled Trial of Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4 Ezetimibe
19 A Randomized Controlled Trial Comparing the Adductor Canal Catheter (ACC) and Intra-articular Catheter (IAC) Following Primary Total Knee Arthroplasty Unknown status NCT02497911 Phase 4 Ropivicaine;Bupivicaine
20 Magnesium Deficiency in Cirrhotic Patients Unknown status NCT01894867 Phase 4
21 The Efficacy and Safety of Ursodeoxycholic Acid (UDCA) Added to the Dipeptidyl Peptidase-4 Inhibitor, Sitagliptin in People With Type 2 Diabetes and Chronic Liver Diseases Unknown status NCT01337440 Phase 4 UDCA;Sitagliptin
22 The Orange-III Trial: Optimised Recovery With Movicol® Preoperatively Within an Enhanced Recovery Programme, a Randomised Controlled Trial Unknown status NCT01429779 Phase 4 Movicol
23 A Study Comparing Thymoglobulin to Tacrolimus in Liver Transplant and Impact on Renal Function Unknown status NCT00564538 Phase 4 anti-thymocyte globulin (rabbit);tacrolimus
24 Sustained Off-treatment Response After HBeAg Loss in HBeAg-Pos Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogues Unknown status NCT01911156 Phase 4 Continue NA treatment;Discontinue NA Treatment
25 Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients-A Randomized, Double-Blinded, Controlled Trial Unknown status NCT01148576 Phase 4 entecavir;entecavir;essentiale + entecavir;Vitamin E + entecavir
26 Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis: An Open Label, Randomized Controlled Trial of Lactulose, Probiotics and No-therapy Unknown status NCT01178372 Phase 4 Lactulose;Probiotics(VSL#3)
27 A Double-Blinded Randomized Controlled Trial Comparing the Adductor Canal Catheter (ACC) and Local Infiltration of Analgesia (LIA) Following Primary Total Knee Arthroplasty Unknown status NCT02603900 Phase 4 ropivacaine;bupivacaine
28 Phase IV Study of Effectiveness of Interferon and Ribavirin Treatment in Thalassemia Major Patients With Chronic Viral Hepatitis C Unknown status NCT00887081 Phase 4 PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin
29 HBsAg Loss/Seroconversion in Low Replicative Chronic HBV Infection Patients With Low Level HBsAg Treated With Peginterferon Alpha Unknown status NCT02908763 Phase 4 peginterferon alfa
30 The Efficacy and Safety Study of Magnesium Isoglycyrrhizinate Injection Followed by Diammonium Glycyrrhizinate Enteric-coated Capsules and Combined With Entecavir on the Treatment of Chronic Hepatitis B Unknown status NCT03349008 Phase 4 Entecavir;Magnesium Isoglycyrrhizinate;Diammonium Glycyrrhizinate;Magnesium Isoglycyrrhizinate Placebo;Diammonium Glycyrrhizinate Placebo
31 Insulin Therapy in the Inpatient Management of Cirrhotic Patients With Type 2 Diabetes Unknown status NCT01143948 Phase 4 Glargine & Glulisine;Regular insulin;NPH & regular insulin
32 The Optimizing Treatment of Peginterferon Alpha in HBeAg-negative Chronic Hepatitis B Virus Patients With Low Level HBsAg Unknown status NCT02893124 Phase 4 peginterferon alfa
33 Efficacy and Safety of Certican® in Combination With Myfortic® in Adult Renal Allograft Recipients Following Calcineurin Inhibitor Withdrawal at Week 16 Compared to Patients Who Are Maintained on Tacrolimus and Myfortic® Unknown status NCT01399242 Phase 4 Certican
34 The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a) Unknown status NCT02501850 Phase 4 Liraglutide;metformin
35 Randomized, Multicenter, Open -Label Clinical Trial to Study the Effect of Adding on Pegylated Interferon Therapy for Patients Diagnosed With Chronic Hepatitis B Showing Maintained Response While Receiving Ongoing Nucleotide Analogues Unknown status NCT02982837 Phase 4 PEG-IFN & Nucleos(t)tide analogues;Nucleos(t)tide analogues
36 Phase IV Study of the Efficacy of Entecavir in Patients With Chronic Hepatitis B Virus Infection and Persistently Normal Alanine Aminotransferase Unknown status NCT01833611 Phase 4 Entecavir;placebo
37 A Randomized Comparison of Two Albumin Administration Schedules for Spontaneous Bacterial Peritonitis Unknown status NCT00761098 Phase 4 Standard Care;Experimental
38 An Efficacy and Safety Study Comparing Pegylated-Interferon and Ribavirin Plus Metformin to Pegylated-Interferon and Ribavirin in the Treatment of naïve Patients With Genotype 1 Chronic HCV Infection and Insulin Resistance Unknown status NCT00370617 Phase 4 metformin
39 A Phase 4, Open-Label Study to Investigate the Efficacy and Safety of Tenofovir Disoproxil Fumarate (Viread(R)) in Preventing Hepatocellular Carcinoma Recurrence in Chronic Hepatitis B Virus Infected Patients With Low Viral Load at Baseline Treated With Radiofrequency Ablation or Resection Unknown status NCT02308319 Phase 4 Tenofovir disoproxil fumarate
40 The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes Unknown status NCT02964715 Phase 4 Empagliflozin
41 Randomized Controlled Trial Comparing Effects of Sedation for Upper Gastrointestinal Endoscopy With Propofol Versus Midazolam on Psychometric Tests and Critical Flicker Frequency in Cirrhotics Unknown status NCT01356121 Phase 4 Propofol;Midazolam
42 RCT of Carvedilol vs Variceal Band Ligation in the Primary Prophylaxis of Oesophageal Variceal Haemorrhage Unknown status NCT01070641 Phase 4 Carvedilol
43 Treating HIV-infected Elite Controllers as a Model of HIV Remission Unknown status NCT01025427 Phase 4 Raltegravir, tenofovir/emtricitabine
44 A Randomised, Open-label Clinical Trial Assessing the Efficacy and Safety of Mycophenolate Mofetil Versus Azathioprine for Induction of Remission in Treatment Naive Autoimmune Hepatitis Unknown status NCT02900443 Phase 4 Mycophenolate mofetil;Azathioprine
45 the Safety and Effect in TB Patients With NAC Unknown status NCT02889757 Phase 4 Acteylcysteine
46 Treatment of Relapsed Acute Promyelocytic Leukemia With Arsenic Trioxide (Phase IV Study) Unknown status NCT00196768 Phase 4 Arsenic trioxide;Trisenox
47 Banlangen Granules Anti-seasonal Influenza Study: a Randomized, Double Blind, Positive and Placebo Controlled,Clinical Study. Unknown status NCT02232945 Phase 4 placebo of oseltamivir phosphate;oseltamivir phosphate;Banlangen (Radix Isatidis) granules;placebo of Banlangen(Radix Isatidis) granules
48 Metformin for Weight Control in Adolescents Taking Atypical Antipsychotics- Double Blind Placebo Controlled Study Unknown status NCT00845936 Phase 4 Metformin
49 Randomized Trial of Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients Who Have Undergone Lamivudine/Adefovir Add-on Treatment Unknown status NCT01491295 Phase 4 Tenofovir disoproxil fumarate;Lamivudine plus adefovir
50 Effect of Liraglutide on Fatty Liver Content Evaluated by Proton-spectroscopy (1H-spectroscopy) and Lipoprotein Kinetic, in Patients With Type 2 Diabetes Unknown status NCT02721888 Phase 4 Liraglutide;MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)

Search NIH Clinical Center for Liver Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


alglucerase
imiglucerase
Medium chain triglycerides

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Liver Disease cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: liver diseases

Genetic Tests for Liver Disease

Genetic tests related to Liver Disease:

# Genetic test Affiliating Genes
1 Hepatic Failure 29
2 Abnormality of the Liver 29

Anatomical Context for Liver Disease

MalaCards organs/tissues related to Liver Disease:

40
Liver, Testes, Kidney, Bone, T Cells, Heart, Endothelial

Publications for Liver Disease

Articles related to Liver Disease:

(show top 50) (show all 50549)
# Title Authors PMID Year
1
Liver diseases in COVID-19: Etiology, treatment and prognosis. 61 42
32476793 2020
2
Alcohol and the Hospitalized Patient. 42
32505260 2020
3
Liver injury in COVID-19: The current evidence. 42
32450787 2020
4
Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease. 54 61
20371660 2010
5
Elevated hydroxyacylcarnitines in a carrier of LCHAD deficiency during acute liver disease of pregnancy - a common feature of the pregnancy complication? 54 61
20363656 2010
6
The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. 54 61
20415685 2010
7
The spectrum of liver diseases related to ABCB4 gene mutations: pathophysiology and clinical aspects. 54 61
20422496 2010
8
The PXR is a drug target for chronic inflammatory liver disease. 54 61
20416375 2010
9
Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis. 61 54
20102716 2010
10
Nonalcoholic fatty liver disease and HFE gene mutations: a Polish study. 54 61
20503453 2010
11
Beneficial effects of exercise training (treadmill) on insulin resistance and nonalcoholic fatty liver disease in high-fat fed C57BL/6 mice. 61 54
20490434 2010
12
Negative correlation between neuropeptide Y/agouti-related protein concentration and adiponectinemia in nonalcoholic fatty liver disease obese adolescents submitted to a long-term interdisciplinary therapy. 61 54
19942238 2010
13
Is alanine aminotransferase level a surrogate biomarker of hepatic apoptosis in nonalcoholic fatty liver disease? 61 54
20406065 2010
14
Hepatic senescence marker protein-30 is involved in the progression of nonalcoholic fatty liver disease. 61 54
19946731 2010
15
Serum apoptotic caspase activity in chronic hepatitis C and nonalcoholic Fatty liver disease. 54 61
19881359 2010
16
Studies of gamma-glutamyl transferase in alpha-1 antitrypsin deficiency. 61 54
20397813 2010
17
Effect of Xuezhikang Capsule on serum tumor necrosis factor-alpha and interleukin-6 in patients with nonalcoholic fatty liver disease and hyperlipidemia. 54 61
20473736 2010
18
Nuclear receptors, inflammation, and liver disease: insights for cholestatic and fatty liver diseases. 61 54
20200515 2010
19
Hepatic expression of thyroid hormone-responsive spot 14 protein is regulated by constitutive androstane receptor (NR1I3). 61 54
20185760 2010
20
Nonlinear distribution of adiponectin in patients with nonalcoholic fatty liver disease limits its use in linear regression analysis. 54 61
19770674 2010
21
The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance. 54 61
20093562 2010
22
Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. 61 54
20335584 2010
23
Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK. 61 54
20150538 2010
24
Natural anticoagulants can be useful predictors of severity in chronic liver disease. 61 54
20019598 2010
25
HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. 54 61
19931264 2010
26
The new therapeutic frontier--nuclear receptors and the liver. 61 54
20133000 2010
27
[Patomechanisms of hepatic steatosis]. 54 61
20159747 2010
28
Macrophage migration inhibitory factor expression and MIF gene -173 G/C polymorphism in nonalcoholic fatty liver disease. 61 54
19829123 2010
29
Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. 61 54
20176643 2010
30
Prevalence of genetic polymorphisms in the promoter region of the alpha-1 antitrypsin (SERPINA1) gene in chronic liver disease: a case control study. 61 54
20170533 2010
31
Association of polymorphisms of glutamate-cystein ligase and microsomal triglyceride transfer protein genes in non-alcoholic fatty liver disease. 61 54
19817962 2010
32
[The roles of cyclooxygenase-2 and 5-lipoxygenase in liver disease]. 61 54
20196963 2010
33
Nonalcoholic fatty liver disease in primary aldosteronism: a pilot study. 54 61
19910932 2010
34
[Is venous thrombembolism during pregnancy an indication for routine assay of antithrombin activity and antithrombin supplementation?]. 61 54
20232702 2010
35
Differential diagnosis of liver diseases using serum biomarkers. 54 61
20414942 2010
36
Influence of amino-acid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1b. 61 54
19950230 2010
37
The nuclear receptor PXR gene variants are associated with liver injury in nonalcoholic fatty liver disease. 54 61
19940802 2010
38
Apoptosis in immune-mediated liver diseases. 61 54
20460903 2010
39
Therapeutic effect of bezafibrate against biliary damage: a study of phospholipid secretion via the PPARalpha-MDR3 pathway. 61 54
20040336 2010
40
The role of cytokines in non-alcoholic fatty liver disease. 61 54
20460908 2010
41
Comparison of modes of prothrombin time reporting in patients with advanced liver disease associated with viral hepatitis. 54 61
19330428 2010
42
Plasma interleukin-18/interleukin-18 binding protein ratio in Chinese with NAFLD. 54 61
20422882 2010
43
Animal models for hepatitis C and related liver disease. 54 61
20156300 2010
44
Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers. 61 54
19793164 2010
45
Tumor necrosis factor-alpha accelerates apoptosis of steatotic hepatocytes from a murine model of non-alcoholic fatty liver disease. 61 54
20043871 2010
46
Variants in the UGT1A1 gene and the risk of pediatric nonalcoholic fatty liver disease. 54 61
19948621 2009
47
Impact of fish oil-based lipid emulsion on serum triglyceride, bilirubin, and albumin levels in children with parenteral nutrition-associated liver disease. 61 54
19687773 2009
48
Dephosphorylation of threonine 38 is required for nuclear translocation and activation of human xenobiotic receptor CAR (NR1I3). 61 54
19858220 2009
49
[Fatty liver disease, insulin resistance and adiponectin in an obese pediatric population]. 54 61
19850541 2009
50
Systematic review: caspase-cleaved fragments of cytokeratin 18 - the promises and challenges of a biomarker for chronic liver disease. 61 54
19769633 2009